The efficacy and safety of zolbetuximab were investigated in two Phase III, randomized, double-blind, placebo-controlled trials (SPOTLIGHT and GLOW) in adults with previously untreated HER2-/CLDN18.2+, locally advanced unresectable or metastatic G/GEJ adenocarcinoma [15,16]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.